Alcresta brings in $49.4m via Series C
Alcresta Inc. (therapies for gastrointestinal disorders and rare diseases) raised $49.4m in its Series C financing to new backer Athyrium and returning shareholders Bessemer Venture Partners, Frazier Healthcare, and...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?